Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuhiro Ishida

Showing results (31-40 of 233) with videos related to

Pageof 24
Sort By:
Cancer Reports (Hoboken, N.J.)|June 26, 2021
A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)Hidenori Ando, Yuta Murakami, Kiyoshi Eshima, et al.
Biological & Pharmaceutical Bulletin|February 5, 2014
Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatinAmr Selim Abu Lila, Hiroshi Kiwada, Tatsuhiro Ishida
International Journal of Pharmaceutics|April 20, 2019
Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivoYusuke Doi, Taro Shimizu, Yu Ishima, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 19, 2006
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injectionTatsuhiro Ishida, Kazutaka Atobe, XingYu Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manageAmr S Abu Lila, Hiroshi Kiwada, Tatsuhiro Ishida
Chemical & Pharmaceutical Bulletin|May 1, 2022
ForewordTatsuhiro Ishida, Kentaro Kogure, Masanori Tachikawa, et al.
Chemical & Pharmaceutical Bulletin|July 3, 2020
Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport SystemYu Ishima, Toru Maruyama, Masaki Otagiri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 4, 2005
Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in ratsXin Yu Wang, Tatsuhiro Ishida, Masako Ichihara, et al.
Advanced Drug Delivery Reviews|August 4, 2020
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticalsGergely Tibor Kozma, Taro Shimizu, Tatsuhiro Ishida, et al.
International Journal of Pharmaceutics|December 25, 2007
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse modelEmi Shiraga, Jose Mario Barichello, Tatsuhiro Ishida, et al.
Pageof 24

Showing results (31-40 of 233) with videos related to

Sort By:
Pageof 24
Cancer Reports (Hoboken, N.J.)|June 26, 2021
A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)Hidenori Ando, Yuta Murakami, Kiyoshi Eshima, et al.
Biological & Pharmaceutical Bulletin|February 5, 2014
Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatinAmr Selim Abu Lila, Hiroshi Kiwada, Tatsuhiro Ishida
International Journal of Pharmaceutics|April 20, 2019
Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivoYusuke Doi, Taro Shimizu, Yu Ishima, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 19, 2006
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injectionTatsuhiro Ishida, Kazutaka Atobe, XingYu Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manageAmr S Abu Lila, Hiroshi Kiwada, Tatsuhiro Ishida
Chemical & Pharmaceutical Bulletin|May 1, 2022
ForewordTatsuhiro Ishida, Kentaro Kogure, Masanori Tachikawa, et al.
Chemical & Pharmaceutical Bulletin|July 3, 2020
Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport SystemYu Ishima, Toru Maruyama, Masaki Otagiri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 4, 2005
Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in ratsXin Yu Wang, Tatsuhiro Ishida, Masako Ichihara, et al.
Advanced Drug Delivery Reviews|August 4, 2020
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticalsGergely Tibor Kozma, Taro Shimizu, Tatsuhiro Ishida, et al.
International Journal of Pharmaceutics|December 25, 2007
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse modelEmi Shiraga, Jose Mario Barichello, Tatsuhiro Ishida, et al.
Pageof 24